Steven Cohen’s Royalty Pharma RPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$65.6M Buy
1,123,256
+1,016,707
+954% +$60M 0.07% 336
2026
Q2
$5.97M Sell
106,549
-383,469
-78% -$20M 0.01% 1636
2026
Q1
$23.5M Sell
490,018
-44,288
-8% -$1.94M 0.03% 717
2025
Q4
$20.6M Buy
+534,306
New +$20.4M 0.02% 865
2025
Q1
– Sell
-249,003
Closed -$7.89M – 2468
2024
Q4
$6.35M Sell
249,003
-277,630
-53% -$7.36M 0.01% 871
2024
Q3
$14.9M Buy
+526,633
New +$14.6M 0.04% 510
2024
Q2
– Sell
-521,200
Closed -$15.8M – 2356
2024
Q1
$15.8M Sell
521,200
-647,600
-55% -$19.1M 0.04% 541
2023
Q4
$32.8M Buy
1,168,800
+440,600
+61% +$12.1M 0.08% 300
2023
Q3
$19.8M Buy
728,200
+198,000
+37% +$5.88M 0.06% 406
2023
Q2
$16.3M Sell
530,200
-88,600
-14% -$3M 0.05% 441
2023
Q1
$22.3M Buy
+618,800
New +$22.9M 0.07% 324
2022
Q2
– Sell
-1,892,900
Closed -$73.7M – 1606
2022
Q1
$73.7M Buy
1,892,900
+1,556,800
+463% +$61.1M 0.29% 80
2021
Q4
$13.4M Buy
336,100
+277,000
+469% +$10.8M 0.05% 433
2021
Q3
$2.14M Buy
+59,100
New +$2.3M 0.01% 784

Other funds holding RPRX

Steven Cohen's RPRX Position: Q3 2026 in Review

Steven Cohen increased its Royalty Pharma (RPRX) stake by 954% in Q3 2026, buying an estimated $60M and bringing the position to 1,123,256 shares worth $65.6M. The position accounts for 0.07% of the portfolio, ranked #336.

Steven Cohen first reported a position in RPRX in Q3 2021 and has held it in 14 quarters since. The position peaked at $73.7M in Q1 2022. 697 funds tracked by Wall St. Rank hold RPRX as of Q3 2026.

  • Steven Cohen held 1,123,256 shares of Royalty Pharma worth $65.6M as of Q3 2026.
  • Steven Cohen bought 1,016,707 Royalty Pharma shares in Q3 2026, an estimated $60M.
  • Royalty Pharma made up 0.07% of Steven Cohen's portfolio in Q3 2026, its #336 holding.
  • Steven Cohen first reported a position in Royalty Pharma in Q3 2021 and has held it in 14 quarters since.
  • Steven Cohen's Royalty Pharma position peaked at $73.7M in Q1 2022.
  • 697 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2026.

Based on Point72 Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.